Cytori Therapeutics Inc., of Austin, Texas, has changed its name to Plus Therapeutics Inc. Its ticker symbol on the Nasdaq Capital Market and for its series S warrants is now PSTV. The company plans a 1-for-50 reverse stock split on Aug. 5. The number of outstanding shares of its common stock is anticipated to change from about 22.2 million to approximately 400,000.

Alvotech ehf, of Reykjavik, Iceland and Cipla Gulf FZ LLC, a wholly-owned subsidiary of Mumbai-based Cipla Ltd., said they have entered into an exclusive partnership for the commercialization of AVT-02, a MAb biosimilar to Humira (adalimumab, Abbvie Inc.), in select emerging markets.

Verastem Oncology Inc., of Boston, said it entered an exclusive licensing deal with Paris-based Sanofi SA to develop and commercialize Copiktra (duvelisib), an oral PI3K-delta/gamma inhibitor, for all oncology indications in Russia and CIS, Turkey, the Middle East and Africa.